| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1537-2995.2002.00017.X |
| P698 | PubMed publication ID | 11896322 |
| P2093 | author name string | Ulla Hedner | |
| Elisabeth Erhardtsen | |||
| P2860 | cites work | Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells | Q28646327 |
| High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. | Q33338284 | ||
| Clinical use of recombinant FVIIa (rFVIIa). | Q33584641 | ||
| Expression of tissue factor procoagulant activity: regulation by cytosolic calcium | Q33785420 | ||
| Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor | Q34059019 | ||
| Deep venous thrombosis in hemophilia A | Q35603455 | ||
| Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors | Q36990492 | ||
| Blood-borne tissue factor: another view of thrombosis | Q37181879 | ||
| Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". | Q37358508 | ||
| Determinants of substrate specificity for factor XIII. | Q41302205 | ||
| Coronary artery disease in severe haemophilia | Q41303111 | ||
| Management of anticoagulation before and after elective surgery | Q41473319 | ||
| Effect of Dextran on Factor VIII (Antihemophilic Factor) and Platelet Function | Q41478402 | ||
| Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries | Q43575604 | ||
| A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group | Q45856561 | ||
| Platelet activity of high-dose factor VIIa is independent of tissue factor | Q45884609 | ||
| Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy | Q45885647 | ||
| Unstable angina associated with factor VIII concentrate therapy for hemophilia A. | Q45886924 | ||
| Use of recombinant factor VIIa in surgery in factor-VII-deficient patients | Q45887181 | ||
| Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. | Q53896354 | ||
| Regulation of extravascular coagulation by microvascular permeability. | Q53902122 | ||
| Treatment of traumatic bleeding with recombinant factor VIIa. | Q55033461 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 114-124 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | Potential role for rFVIIa in transfusion medicine | |
| P478 | volume | 42 |
| Q83232969 | 7 Procoagulators |
| Q36462093 | A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions |
| Q37095548 | A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery |
| Q36328387 | Acquired coagulation inhibitor-associated bleeding disorders: an update |
| Q36497382 | Acquired hemophilia A. |
| Q73142092 | Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device |
| Q35792538 | Aortic valve replacement in a Jehovah's Witness: a case of multi-disciplinary clinical management for bloodless surgery |
| Q45863907 | Change of coagulation after NovoSeven® use for bleeding during cardiac surgery |
| Q35578941 | Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings |
| Q35673520 | Coagulation defects in trauma patients: etiology, recognition, and therapy |
| Q89501345 | Comparison of Neonatal and Adult Fibrin Clot Properties between Porcine and Human Plasma |
| Q33358457 | Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients |
| Q36646985 | Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief review |
| Q46252055 | Emergency reversal of antithrombotic treatment |
| Q37082212 | Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents |
| Q45872689 | Excision of pseudotumour in a patient with haemophilia A and inhibitor managed with recombinant factor VIIa |
| Q47642467 | Fish as bioreactors: transgene expression of human coagulation factor VII in fish embryos. |
| Q47361171 | Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. |
| Q88187780 | Implementation of an off-label recombinant factor VIIa protocol for patients with critical bleeding at an academic medical center |
| Q56905156 | Liver trauma |
| Q36349585 | Management of bleeding emergencies: when to use recombinant activated factor VII. |
| Q73690484 | Mechanism of action of recombinant factor VIIa |
| Q44963707 | Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h. |
| Q37807082 | Novel approaches to the treatment of intracerebral haemorrhage |
| Q38267207 | NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia |
| Q45865634 | Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report). |
| Q33359927 | Pharmacological alternatives to blood transfusion: what is new about? |
| Q35666533 | Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature |
| Q35839531 | Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding |
| Q37898741 | Recombinant activated factor VII as a promising adjuvant therapy for postpartum hemorrhage in the practice of obstetric anesthesia: experience from a university hospital in Taiwan |
| Q33365354 | Recombinant activated factor VII in patients at high risk of bleeding |
| Q33394197 | Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience |
| Q80417711 | Recombinant coagulation factor VIIa in the management of bleeding in patients with von Willebrand disease type 2A |
| Q26822857 | Recombinant factor VIIa as haemostatic therapy in advanced liver disease |
| Q35138036 | Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients |
| Q51240376 | Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. |
| Q33370641 | Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin |
| Q50787850 | Recombinant factor VIIa for refractory bleeding following orthotopic heart transplantation. |
| Q24201292 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q24236583 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q24245204 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q24247865 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q36570888 | Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review |
| Q36077574 | Recombinant factor VIIa in the treatment of non-hemophiliac bleeding |
| Q46473807 | Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores |
| Q36412132 | Recombinant factor VIIa: a review on its clinical use. |
| Q35771690 | Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors |
| Q36603284 | Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome |
| Q42112270 | Redistribution and hemostatic action of recombinant activated factor VII associated with platelets. |
| Q36912173 | Safety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhage |
| Q30833127 | The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. |
| Q45862242 | The Effect of Recombinant Factor VIIa on Noncoagulopathic Pigs with Grade V Liver Injuries |
| Q35211987 | The first case of postpartum acquired hemophilia A in Korea |
| Q48843844 | The independent association of massive blood loss with mortality in cardiac surgery |
| Q36784987 | The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review |
| Q37416007 | The use of recombinant activated factor VII in platelet disorders: a critical review of the literature |
| Q37183517 | The use of recombinant activated factor VII in platelet-associated bleeding |
| Q38005104 | Timely 'off-label' use of recombinant activated factor VII (NovoSeven(®)) can help in avoiding hysterectomy in intractable obstetric bleeding complicated with disseminated intravascular coagulation: A case report and review of the literature |
| Q33362187 | Transfusion medicine service policies for recombinant factor VIIa administration |
| Q35047211 | Transfusion medicine: looking to the future |
| Q35185225 | Treating coagulopathy in trauma patients |
| Q36945941 | Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal |
| Q37900080 | Update and new developments in the management of the exsanguinating patient |
| Q35924900 | Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant |
| Q35670771 | Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient |
| Q45887641 | Use of recombinant activated factor VII for intractable bleeding in patients without hemophilia: A developing country tertiary care center's experience |
| Q46936611 | Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair |
| Q80001271 | [Recommendations of the European Stroke Initiative for the diagnosis and treatment of spontaneous intracerebral haemorrhage] |
| Q45963998 | [Reversal of acenocoumarol anticoagulation with activated factor VII in massive hemorrhage following rupture of a splenic artery pseudoaneurysm] |
Search more.